ICH M12: Pharma industry wants clarity on rifampin dosing, more information on biomarkers

Regulatory NewsRegulatory NewsClinical TrialsComplianceGlobalPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy